Baseline patient characteristics (N = 65)
| Characteristic . | No. . | Percentage . |
|---|---|---|
| Median age, y (range) | 83 (70-91) | |
| Age, y | ||
| 70-79 | 12 | 18.5 |
| 80-84 | 30 | 46.1 |
| >85 | 23 | 35.4 |
| Median hemoglobin level, g/dL (range) | 12.3 (7.6-15.3) | |
| Median creatinine level, mg/dL (range) | 0.9 (0.4-3.5) | |
| Median WBC level, 109/L (range) | 7.0 (1.3-28.5) | |
| Median ANC, 109/L (range) | 5.0 (0.2-24.0) | |
| Sex, male | 30 | 46.1 |
| Systemic symptoms presence | 21 | 33.3 |
| ECOG PS >1 | 15 | 23.1 |
| Stage III-IV | 47 | 72.3 |
| ENS >1 | 14 | 21.5 |
| Largest diameter of lymph nodes >6 cm | 20 | 32.8 |
| LDH > ULN | 32 | 51.6 |
| IPI 3-5 | 35 | 56.4 |
| EPI | ||
| Intermediate risk | 22 | 36 |
| High risk | 39 | 64 |
| HBV serology status∗ | ||
| HBsAb neg/HbcAb neg | 37 | 65.0 |
| HBsAb neg/HBcAb pos (1 HBV-DNA pos) | 6 | 10.5 |
| HBsAb pos/HBcAb neg | 3 | 5.2 |
| HBsAb pos/HBcAb pos | 11 | 19.3 |
| HBV serology positive (total) | 20 | 35 |
| ADL score | ||
| 6 | 36 | 59 |
| 5 | 51 | 34 |
| ≤4 | 4 | 7 |
| IADL score | ||
| 8 | 15 | 25 |
| 6-7 | 38 | 62 |
| ≤5 | 8 | 13 |
| CIRS | ||
| Number of comorbidities grade ≥2: | ||
| 0/4 | 34 | 56 |
| 5 | 18 | 29 |
| 6/8 | 9 | 15 |
| Number of comorbidities grade ≥3: | ||
| 1 | 5 | 8 |
| 2 | 1 | 2 |
| COO based on Hans algorithm | ||
| GCB | 29 | 48 |
| Non-GCB | 32 | 52 |
| Characteristic . | No. . | Percentage . |
|---|---|---|
| Median age, y (range) | 83 (70-91) | |
| Age, y | ||
| 70-79 | 12 | 18.5 |
| 80-84 | 30 | 46.1 |
| >85 | 23 | 35.4 |
| Median hemoglobin level, g/dL (range) | 12.3 (7.6-15.3) | |
| Median creatinine level, mg/dL (range) | 0.9 (0.4-3.5) | |
| Median WBC level, 109/L (range) | 7.0 (1.3-28.5) | |
| Median ANC, 109/L (range) | 5.0 (0.2-24.0) | |
| Sex, male | 30 | 46.1 |
| Systemic symptoms presence | 21 | 33.3 |
| ECOG PS >1 | 15 | 23.1 |
| Stage III-IV | 47 | 72.3 |
| ENS >1 | 14 | 21.5 |
| Largest diameter of lymph nodes >6 cm | 20 | 32.8 |
| LDH > ULN | 32 | 51.6 |
| IPI 3-5 | 35 | 56.4 |
| EPI | ||
| Intermediate risk | 22 | 36 |
| High risk | 39 | 64 |
| HBV serology status∗ | ||
| HBsAb neg/HbcAb neg | 37 | 65.0 |
| HBsAb neg/HBcAb pos (1 HBV-DNA pos) | 6 | 10.5 |
| HBsAb pos/HBcAb neg | 3 | 5.2 |
| HBsAb pos/HBcAb pos | 11 | 19.3 |
| HBV serology positive (total) | 20 | 35 |
| ADL score | ||
| 6 | 36 | 59 |
| 5 | 51 | 34 |
| ≤4 | 4 | 7 |
| IADL score | ||
| 8 | 15 | 25 |
| 6-7 | 38 | 62 |
| ≤5 | 8 | 13 |
| CIRS | ||
| Number of comorbidities grade ≥2: | ||
| 0/4 | 34 | 56 |
| 5 | 18 | 29 |
| 6/8 | 9 | 15 |
| Number of comorbidities grade ≥3: | ||
| 1 | 5 | 8 |
| 2 | 1 | 2 |
| COO based on Hans algorithm | ||
| GCB | 29 | 48 |
| Non-GCB | 32 | 52 |
Percentages may not correspond to 100% because of rounding.
ADL, 6 items; IADL, 8 items.
ADL, activities of daily living; ANC, absolute neutrophil count; CIRS, Cumulative Illness Rating Scale; ECOG PS, Eastern Cooperative Oncology Group performance status; ENS, extranodal site of involvement; EPI, Elderly Project Index; HBc, hepatitis B core (antigen); HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IADL, instrumental activities of daily living; IPI, international prognostic index; neg, negative; LDH, lactate dehydrogenase; pos, positive; ULN, upper limit of normal; WBC, white blood cell.
All 65 patients tested HBsAg negative; serology was tested in 57 patients.